Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    Endocrine Society Releases Guideline on Diagnosis, Treatment of Primary Aldosteronism - (DGNews)
    TopAbstracts in Hypertension 08/27/2008 - (DGNews)
    Preliminary Study Shows Allopurinol Lowers Blood Pressure in Adolescents With Hypertension - (DGNews)
    TopAbstracts in Hypertension 08/20/2008 - (DGNews)
    Teens With Low Sleep Efficiency at Risk for Hypertension, Cardiovascular Disease - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • Late Breaking Data From Clinical Trials on RAAS Inhibition
    • Understanding Metabolic Syndrome: Knowing the Risks
      The Neglected Field of Prehypertension, Pathophysiology and Clinical Impact
      Rationale for Lowering Blood Pressure
      Hypertension 2007: Lessons from Observational Studies and Clinical Trials to Guide Patient Care

      Webcasts/CME archive

       Recent cases - Hypertension
        Transient Left Ventricular Apical Ballooning and Exercise Induced Hypertension During Treadmill Exercise Testing: Is There a Common Hypersympathetic Mechanism?
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion
        A Case of Hyperreninemic Hypertension with Bilateral Positive Captopril Renography but without Renovascular Stenosis

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Eplerenone Alone Or Combined With Enalapril Effectively Reduces Left Ventricular Hypertrophy

        A DGReview of :"Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. The 4E-Left Ventricular Hypertrophy Study"
        Circulation

        10/13/2003
        By Jill Taylor


        In patients with essential hypertension, eplerenone alone or in combination with an ACE inhibitor appears to be a promising therapy for reducing left ventricular hypertrophy (LVH), thus reducing morbidity and mortality.

        Reversal of LVH is an important goal of antihypertensive therapy. Although elevated renin-angiotensin-aldosterone system activity has been shown to correlate with LVH and cardiovascular risk, the relative contributions of angiotensin II and aldosterone are unclear.

        In a 9-month study of hypertensive patients with LVH, Bertram Pitt, MD, of the University of Michigan Medical School in Ann Arbor, Michigan, United States, and colleagues compared left ventricular (LV) mass reduction during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination.

        A total of 202 LVH patients with a history of hypertension were randomised to receive eplerenone 200 mg daily, enalapril 40 mg daily, or eplerenone 200 mg and enalapril 10 mg daily after a 14 day run-in period on placebo.

        In cases where BP failed to normalise (diastolic blood pressure [DBP] >90 mmHg or systolic blood pressure [SBP] >180 mmHg) by week 8, open-label hydrochlorothiazide (HCTZ) 12.5 to 25 mg, amlodipine 10 mg, or a combination was administered.

        The primary study endpoint was assessment by magnetic resonance imaging of change in LV mass. Additionally, change in blood pressure, renin-angiotensin-aldosterone system hormones, albuminuria, and safety were evaluated.

        Comparison of monotherapies showed that eplerenone and enalapril were similar in efficacy. Eplerenone significantly reduced LV mass from baseline (-14.5 ± 3.36 g; n=50), as did enalapril (-19.7 ± 3.20 g; n=54; P=0.258). Combination therapy with eplerenone/enalapril (-27.2 ± 3.39 g; n=49) was more effective than eplerenone alone (P=0.007).

        Significant reductions from base line were observed for all treatment groups in mean SBP and DBP. Adverse reactions were reported with similar incidence between treatment groups.

        The study was supported by a grant from Pharmacia Corp.
        Circulation. 2003 Sep 29 [Epub ahead of print]. "Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. The 4E-Left Ventricular Hypertrophy Study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send